Highlights in Advanced Prostate Cancer From the 2019 ASCO Genitourinary Cancers Symposium.
Authors: PMID: 32692734 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 24, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in Advanced Prostate Cancer from the 2019 ASCO Genitourinary Cancers Symposium: Commentary.
Authors: George DJ PMID: 32692735 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 24, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on drugs in advanced ovarian cancer.
Authors: O'Malley D PMID: 32649652 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in CAR T-cell therapy for the treatment of multiple myeloma.
Authors: Shah N PMID: 32649653 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

EGFR inhibition in colorectal cancer with liver metastasis.
Authors: Grothey A PMID: 32649654 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The current status of secondary cytoreduction in ovarian cancer: a systematic review.
CONCLUSIONS: Secondary cytoreduction remains a viable treatment option for select patients for now, but this is entirely dependent on the highly anticipated overall survival results of DESKTOP III and SOC 1. PMID: 32649655 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Richter transformation of chronic lymphocytic leukemia in the era of novel agents.
Authors: Wang Y, Ding W Abstract The increased use of several effective novel targeted therapy agents has revolutionized therapy for patients with chronic lymphocytic leukemia (CLL). Disease progression in patients with CLL continues to occur, however. In particular, 3% to 25% of patients treated with a novel agent develop Richter transformation (RT); that is, histologic transformation of CLL to an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). RT that develops in the novel agent era is frequently associated with adverse molecular alterations, such as TP53 disruption and complex karyotype...
Source: Clinical Advances in Hematology and Oncology - July 12, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

CLL in focus.
Authors: Schuyler D PMID: 32628646 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Assessing the risk of heart failure in patients with acute leukemia.
Authors: Scherrer-Crosbie M PMID: 32628647 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.
Authors: Zhang T, George DJ PMID: 32628648 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging role of immunotherapy in locally advanced non-small cell lung cancer.
Authors: Mulherkar R, Grewal AS, Berman AT Abstract Non-small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC have locally advanced or metastatic disease at the time of diagnosis. The 5-year overall survival rate for patients with locally advanced NSCLC is 15% to 20%. The traditional treatment paradigm for unresectable locally advanced NSCLC consists of platinum-based chemotherapy with concurrent radiation. Evidence from phase 3 clinical trials has established a role for immunotherapy after chemoradiation, and emerging data continue to eluci...
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.
Authors: Laurence J Abstract Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that is driven by uncontrolled activation of the alternative complement pathway, classically in the context of a genetic or autoimmune complement abnormality. Initial guidelines suggested lifelong treatment with the C5 inhibitor eculizumab, which until recently was the only therapy approved by the US Food and Drug Administration and European Medicines Agency for aHUS. However, multicenter observational studies provide compelling evidence that discontinuation of eculizumab, with careful monitoring for recurre...
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

COVID-19 in hem/onc news.
Authors: Schuyler D PMID: 32628651 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How we treat left-sided vs right-sided colon cancer.
Authors: Hanna DL, Lenz HJ PMID: 32628652 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Providing oncology care during the COVID-19 pandemic.
Authors: Lyman GH PMID: 32628653 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Strategies to overcome resistance to PD-1 inhibitors.
Authors: Gajewski TF PMID: 32628654 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Improving outcomes with checkpoint blockade in non-Hodgkin lymphoma.
Authors: Brody J PMID: 32628655 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in borderline resectable pancreatic adenocarcinoma.
Authors: Vadehra D, Salibi PN, McHaffie DR, Sulzer J, Iannitti DA, Hwang JJ Abstract Pancreatic adenocarcinoma is one of the most lethal cancers in oncology. Pancreatic cancer is the third most common cause of cancer-related mortality in the United States. As the years have progressed, the importance of a multidisciplinary and multimodal approach to pancreatic cancer care has been recognized and is now recommended in all major society guidelines. A subset of pancreatic cancer, borderline resectable pancreatic cancer (BRPC), has emerged as a distinct clinical entity for which specialized treatment plans are now bein...
Source: Clinical Advances in Hematology and Oncology - July 7, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Inclusion of biopsies in clinical trials of oncology drugs.
Authors: Tam AL PMID: 32609661 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 3, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How disease stage impacts the rate of second primary malignancies in patients with diffuse large B-cell lymphoma.
Authors: Kamdar M PMID: 32609662 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 3, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Prostate cancer in African American men.
Authors: Patierno SR PMID: 32609663 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 3, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights from the 2019 San Antonio Breast Cancer Symposium.
Authors: Rugo HS PMID: 32609664 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 3, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Reflections on 45 years as a clinical hematologist.
Authors: Boxer M PMID: 32609665 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - July 3, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Authors: Moffat GT, O'Reilly EM Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that remains a challenge to treat. In pursuit of personalized medicine, researchers continue active exploration of the genetic and molecular framework of PDAC to apply novel therapeutics and enhance outcomes. In patients who have PDAC, germline mutations-such as those in the BRCA1/2 and PALB2 genes-are predominantly associated with the DNA damage response and repair pathway. On the basis of studies completed in patients with BRCA-mutated advanced breast and ovarian cancer, the poly(ADP-ribose) polymerase (PA...
Source: Clinical Advances in Hematology and Oncology - July 3, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in kidney cancer from the Eighteenth International Kidney Cancer Symposium.
Authors: PMID: 32558799 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 20, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in nonmalignant hematology from the 2019 American Society of Hematology meeting.
Authors: Kessler CM PMID: 32558800 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 20, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

News in the treatment of chronic lymphocytic leukemia.
Authors: Schuyler D PMID: 32558801 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 20, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of maintenance therapy in ovarian cancer.
Authors: Oza AM PMID: 32558802 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 20, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of HIPEC in patients with advanced colorectal cancer.
Authors: Bartlett DL, Ryan DP PMID: 32558803 [PubMed - as supplied by publisher] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 20, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Second-line treatment for metastatic pancreatic cancer.
Authors: Paluri RK, Kasi A, Young C, Posey JA Abstract Pancreatic cancer is the fourth-leading cause of cancer-related death. It is commonly diagnosed at an advanced stage, when no curative options exist. Over the last decade, combination chemotherapy has shown a survival benefit compared with single-agent gemcitabine and has become established as first-line therapy in metastatic pancreatic cancer. The choice of frontline regimen, which is based on clinical factors, plays an important role in subsequent management. Limited second-line standard therapeutic options are available. Studies have not definitively establi...
Source: Clinical Advances in Hematology and Oncology - June 20, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Focal therapy for prostate cancer: recent advances and future directions.
Authors: Wang A, O'Connor LP, Yerram NK, Nandanan N, Ahdoot M, Lebastchi AH, Gurram S, Chalfin H, Pinto PA Abstract Prostate cancer is the most frequently diagnosed cancer in men after skin cancer. Owing to the rising popularity of prostate-specific antigen screening, large numbers of patients are receiving a diagnosis of prostate cancer and undergoing whole-gland treatment. Some patients with a diagnosis of low-risk, localized disease may not benefit from whole-gland treatment, however, given its known morbidity. In response to advances in prostate imaging and evidence suggesting that the prognosis in prostate can...
Source: Clinical Advances in Hematology and Oncology - June 20, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How gradual retirement has allowed me to spend more time with family and being physically active.
Authors: Bunn PA PMID: 32511217 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 10, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of direct oral anticoagulants in antiphospholipid syndrome.
Authors: Cohen H PMID: 32511218 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 10, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The standard of care for brain metastases in melanoma.
Authors: Tawbi H PMID: 32511219 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 10, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Emerging therapeutic targets in follicular lymphoma.
Authors: Wendel HG PMID: 32511220 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - June 10, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Cold agglutinin disease: where do we stand, and where are we going?
Authors: Berentsen S, Malecka A, Randen U, Tjønnfjord GE Abstract Primary cold agglutinin disease (CAD) is characterized by a very indolent bone marrow clonal B-cell lymphoproliferative disorder that initiates an autoimmune hemolytic anemia. The clonal B cells produce a monoclonal autoantibody termed cold agglutinin, most often of the immunoglobulin (Ig) Mκ class. After binding to its antigen, the IgM initiates a complement classical pathway-driven erythrocyte destruction, predominantly mediated by opsonization with complement protein C3b and extravascular hemolysis in the liver. We review the molecula...
Source: Clinical Advances in Hematology and Oncology - June 10, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Perioperative approaches to kidney cancer.
This article provides an overview of the perioperative treatment strategies available for renal cancer. A review of the literature via PubMed, ClinicalTrials.gov, the American Urological Association, and the American Society of Clinical Oncology was used to evaluate the perioperative treatment modalities that best fit renal malignancies according to subtype and stage. For metastatic renal cell carcinoma, among other cancer types, the advent of novel targeted molecular therapies has completely changed the therapeutic landscape. Therapy directed against vascular endothelial growth factor receptor (VEGFR), mammalian target of...
Source: Clinical Advances in Hematology and Oncology - June 10, 2020 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of comprehensive molecular profiling in colorectal cancer.
Authors: Hochster HS PMID: 31851152 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in the development of vaccines and other immunotherapies for multiple myeloma.
Authors: Avigan DE PMID: 31851153 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Prophylaxis of central nervous system relapse in patients with lymphoma.
Authors: Kallam A PMID: 31851154 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Becoming a surgeon-scientist: my transition from fellowship to faculty.
Authors: Previs RA PMID: 31851155 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Smoking cessation after a cancer diagnosis.
Authors: Buckles DM PMID: 31851156 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment-free remission in chronic myeloid leukemia.
Authors: Molica M, Naqvi K, Cortes JE, Paul S, Kadia TM, Breccia M, Kantarjian H, Jabbour EJ Abstract Tyrosine kinase inhibitors (TKIs) represent a major breakthrough in the treatment of chronic myeloid leukemia (CML). Thanks to these agents, CML has been transformed from a disease with limited treatment options and a dismal prognosis into a more indolent disease with survival comparable to that of the general population. The need for ongoing TKI therapy remains controversial for several reasons, including cost and toxicity. Studies in CML patients with a sustained deep molecular response have demonstrated that sto...
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer.
Authors: Ericson KJ, Murthy PB, Bryk DJ, Ramkumar RR, Broughman JR, Khanna A, Mian OY, Campbell SC Abstract Bladder-sparing therapies for the treatment of nonmetastatic muscle-invasive bladder cancers are included in both American and European guidelines. Numerous treatment approaches have been described, including partial cystectomy, radiation monotherapy, and radical transurethral resection. However, the most oncologically favorable and well-studied regimen employs a multimodal approach that consists of maximal transurethral resection of the bladder tumor followed by concurrent radiosensitizing chemotherapy and r...
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment of early-stage hormone receptor-positive breast cancer.
Authors: Rugo HS PMID: 31851159 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Authors: Kasner MT PMID: 31851160 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Assessing the risk of cognitive impairment among men with prostate cancer.
Authors: Ryan C PMID: 31851161 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Targeting the KRAS G12C mutation in patients with advanced solid tumors.
Authors: Hong DS PMID: 31851163 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

HIV protease inhibitors for the treatment of multiple myeloma.
Authors: Mendez-Lopez M, Sutter T, Driessen C, Besse L Abstract Outcomes in multiple myeloma (MM) patients have improved in recent years owing to the introduction of new drugs. Among them, proteasome inhibitors and immunomodulatory imide drugs have become central in the management of newly diagnosed and relapsed MM. However, resistance to these classes of agents develops in most patients and ultimately leads to death from relapsed/refractory disease. A need exists for new classes of antimyeloma drugs, especially ones that are active in the multirefractory setting. The conventional drug development process, which in...
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Molecular pathways and targeted therapy in cholangiocarcinoma.
Authors: Dabney RS, Khalife M, Shahid K, Phan AT Abstract Cholangiocarcinoma (CCA) encompasses a rare group of malignancies arising from epithelial cells lining the biliary tree that connects the liver and gallbladder to the small intestine. Most patients present with advanced incurable disease that has a poor prognosis, and standard treatment options remain limited. Effective nontoxic treatment options for advanced CCA are needed. Fibroblast growth factors (FGFs) and their fibroblast growth factor receptor (FGFR) pathways are crucial to cellular proliferation, cellular survival, and differentiation of many maligna...
Source: Clinical Advances in Hematology and Oncology - December 19, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research